403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Intranasal Corticosteroids Market To Sustain USD 11.57 Billion By 2034, Driven By Rising Allergic Rhinitis Cases
| Table | Scope | |
| Market Size in 2025 | USD 7.57 Billion | |
| Projected Market Size in 2034 | USD 11.57 Billion | |
| CAGR (2025 - 2034) | 4.84 | % |
| Leading Region | North America by 40% | |
| Market Segmentation | By Product Type/Formulation, By Active Ingredient/Drug Molecule, By Indication/Therapeutic Use, By Channel/Distribution, By Region | |
| Top Key Players | Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Viatris/Mylan, Cipla Limited, Novartis AG, Boehringer Ingelheim, Lupin Pharmaceuticals, Sun Pharmaceutical Industries, Sandoz / generic steroid producers, Hikma Pharmaceuticals, Almirall, Perrigo |
Major Growth Drivers:
What major factors are driving the rapid growth of the INCS market?
- Increasing prevalence of allergic airway diseases: The rising healthcare burden of allergic rhinitis, chronic sinusitis and nasal polyps, impacted by urbanization, air pollution, and climate change, is contributing significantly to the demand for efficacious intranasal therapies. Continuing trend towards self-care and over the counter (OTC) access: A grant number of INCS products are now available OTC, supporting the patient's preference for self-administered, non-invasive therapies, ultimately resulting in decreased dependence on systemic therapies. Innovations in delivery technologies: Pharmaceutical companies are beginning to invest in preservative-free nasal sprays, non-aerosol delivery systems, and smart nasal applicators that are not only more comfortable for the patient, but also help promote better compliance and adherence to therapy. The pipeline of biosimilars and new molecules: There is a strong incentive to develop biosimilar versions of existing intranasal corticosteroids in conjunction with new molecules Favorable reimbursement and healthcare infrastructure: In particular, within developed regions of the world, favorable reimbursement frameworks and their incorporation into existing clinical practice guidelines, facilitate patient access to therapy and foster long-term sustainable use of therapy.
Key Drifts
What are the main trends ('key drifts') you are seeing in the INCS market?
- A significant trend is toward combination intranasal sprays (corticosteroids + antihistamines, such as fluticasone + azelastine) that are intended for multi-symptom (or treatment resistant) allergic rhinitis. We are also witnessing non-aerosol, preservative-free formulations that are intended to limit irritation and enhance the end-user experience. Moreover, smart delivery devices that are combined with a digital health platform (e.g., app-connected applicators) are under investigation for potential to support adherence, enhance delivery, and improve the clinical outcome. We are also seeing an expanded exploration of intranasal delivery modalities for novel uses, such as CNS-targeted delivery and immunomodulation, which expands the potential utility of the nasal corticosteroid delivery platform.
Significant Challenge:
The fast-moving consumer goods market for INCS faces numerous challenges, one of the most significant is regulatory hurdles and burdens surrounding the clinical data requirements for biosimilar or novel approvals
Regional Analysis:
North America leads the intranasal corticosteroids market thanks to high allergic rhinitis and sinusitis prevalence, a developed healthcare system, and robust insurance reimbursement for these nasal therapies. Many intranasal corticosteroids offered in the U.S. are available over-the-counter, which fosters consumer self-care and ongoing usage, setting the U.S. market apart from other countries. Clinical guidelines in North America also recommend intranasal corticosteroids as the standard for therapy, contributing to widespread adoption. Additionally, leading companies are launching formulation enhancements, smart delivery devices, and product combinations that cater to user preference, an important consideration of these therapies.
In Asia-Pacific, intranasal corticosteroids is expected to be the fastest-growing region, driven by strong projected CAGRs in the coming years. Demand for suitable and effective nasal therapy will be driven by quick and rapid urbanization, increased pollution, and growing rates of allergic sensitization, among other contributing factors. Similarly, increasing disposable income and expanding healthcare infrastructure will lead to an increase in accessibility to prescription and over-the-counter (OTC) intranasal corticosteroids (INCS) product options. Lastly, local pharmaceutical companies
Get the latest insights on life science industry segmentation with our Annual Membership:Segmental Insights:
By Product Type / Formulation:
This continues as the backbone of the INCS market, projected to maintain about 65% revenue share in 2024. Nasal sprays are a well-known dosage form, patient-friendly, and remain available due to decades of clinical use, making them the preferred administration route for allergic rhinitis.
Newer innovation, preservative-free sprays, non-aerosol applicators, and smart delivery devices areas which are expected to grow rapidly. These new delivery forms are meant to enhance comfort, adherence, and dosing accuracy, especially for children or elderly patients who may react differently to standard nasal sprays.
By Active Ingredient / Drug Molecule:
Fluticasone (propionate or furoate) accounted for approximately 28% of share of the INCS market by active ingredient in 2024. Its success can be attributed to its proven efficacy-safety profile, long-term presence in the marketplace, and availability both as prescription and OTC products.
This segment is expected to experience the highest growth rates between 2025 and 2034, as it relates to the development of biosimilars, various new corticosteroid analogues and new combination therapies that enhance the midvention of various new combination therapies that enhance the prevention on renovation development of previously patent-expired products.
By Indication / Therapeutic Use:
This is the largest segment by indication of INCS use and was responsible for approximately 52% of the global revenue of INCS in 2024. The high prevalence of both seasonal and perennial allergic rhinitis, along with guidelines recommendations for INCS use, help to maintain its leadership position.
Among the sub-indications, pediatric allergic rhinitis is expected to grow at the highest rates during the projection period. The increase in diagnosis rates, parental awareness and the availability of child appropriate formulations (for example, gentle sprays) are all contributing to rapid adoption within this population.
By Channel / Distribution:
In 2024, retail pharmacies (physical locations) captured a substantial 56% share of the INCS marketplace. The overall share is quite consistent with typical purchasing behavior for nasal sprays, particularly those that are over-the-counter.
The online pharmacy channel will be the fastest-growing overall channel from 2025–2034. This growth is driven by increased accessibility, convenience, and acceptance of digital pharmacies. The growth of e-pharmacy will ultimately reach a broader audience, particularly younger and more technically prone consumers in regions that support e-pharmacies.
Browse More Insights of Towards Healthcare:
The global microbial fermentation technology market
The global respiratory disease vaccine market
The medical disposable positioning products market
The brain health supplements market
The non-steroidal anti-inflammatory drugs (NSAIDs) market
The legal marijuana market
The global vaccines market
The global drugs market
The U.S. cell therapy market
The global diabetes drugs market
Recent Developments:
In June 2025, Mosanna, a biotech firm, raised US$ 80 million in Series A funding in June 2025 to develop a novel night-time intranasal spray for obstructive sleep apnea, highlighting expansion of INCS applications beyond allergic rhinitis.
Intranasal Corticosteroids Market Key Players List:
- Merck & Co. Inc. Bayer AG Teva Pharmaceutical Industries Ltd. Viatris/Mylan Cipla Limited Novartis AG Boehringer Ingelheim Lupin Pharmaceuticals Sun Pharmaceutical Industries Sandoz / generic steroid producers Hikma Pharmaceuticals Almirall Perrigo
Segments Covered in the Report
By Product Type/Formulation
- Nasal Sprays Nasal Aerosols/Inhalers Nasal Drops Combination Formulations Novel Delivery Forms
By Active Ingredient/Drug Molecule
- Fluticasone Budesonide Mometasone Triamcinolone Beclomethasone Flunisolide/Ciclesonide/Others New Molecules/Biosimilar Versions
By Indication/Therapeutic Use
- Allergic Rhinitis Nasal Polyps Nonallergic Rhinitis/Vasomotor Rhinitis Sinusitis Adjunct Adjunctive in Asthma/COPD Pediatric Allergic Rhinitis
By Channel/Distribution
- Retail Pharmacies Hospital & Institutional Pharmacies E-commerce/Online Pharmacies Clinics/ENT Specialist Outlets Others
By Region
- North America
- U.S. Canada
- China Japan India South Korea Thailand
- Germany UK France Italy Spain Sweden Denmark Norway
- Brazil Mexico Argentina
- South Africa UAE Saudi Arabia Kuwait
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment